Inactive Instrument
IRLAB Therapeutics AB Stock Nasdaq Stockholm
Stocks
Pharmaceuticals
OTC Markets Traded|
End-of-day quote
Nasdaq Stockholm
|
||
| - SEK | - |
|
| 08-19 | Irlab's IRL757 is assigned the name linepemat by WHO | FW |
| 07-08 | Irlab board member James Gamgort buys shares for just under SEK 0.3m | FW |
| Market Cap | 258M 27.17M 23.29M 21.8M 19.92M 37.62M 2.6B 38.01M 100M 1.31B 102M 99.78M 4.36B | P/E 2026 * |
-
| P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 258M 27.17M 23.29M 21.8M 19.92M 37.62M 2.6B 38.01M 100M 1.31B 102M 99.78M 4.36B | EV / Sales 2026 * |
2.53x | EV / Sales 2027 * | 1.82x |
| Free-Float |
86.32% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: IRLAB Therapeutics AB
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 2024-07-31 | |
Susanna Waters
PRN | Corporate Officer/Principal | 60 | 2012-12-31 |
Clas Sonesson
CTO | Chief Tech/Sci/R&D Officer | 65 | 2015-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Rein Piir
BRD | Director/Board Member | 68 | 2015-12-31 |
| Chairman | 73 | 2020-05-06 | |
| Chairman | 68 | 2023-02-19 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.67% | +5.66% | +75.21% | +125.34% | 1,119B | |
| +1.04% | +4.87% | +52.29% | +65.95% | 651B | |
| -0.17% | +6.04% | +25.60% | +79.85% | 468B | |
| -1.38% | +4.31% | +41.64% | +41.08% | 374B | |
| -0.52% | +3.53% | +24.32% | +40.27% | 302B | |
| -1.06% | +5.67% | +1.19% | +12.44% | 259B | |
| +1.03% | +6.90% | +51.11% | +72.46% | 238B | |
| -0.53% | +1.54% | -17.77% | -54.10% | 208B | |
| +0.42% | +6.06% | +27.86% | +90.47% | 181B | |
| Average | -0.19% | +5.17% | +31.27% | +52.64% | 422.21B | |
| Weighted average by Cap. | -0.08% | +5.40% | +43.93% | +72.03% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 102M 10.75M 9.21M 8.62M 7.88M 14.88M 1.03B 15.03M 39.66M 516M 40.35M 39.47M 1.72B | 142M 14.94M 12.81M 11.99M 10.96M 20.69M 1.43B 20.9M 55.14M 718M 56.09M 54.87M 2.4B |
| Net income | -32.6M -3.43M -2.94M -2.76M -2.52M -4.76M -329M -4.81M -12.68M -165M -12.89M -12.61M -551M | 33.3M 3.51M 3.01M 2.81M 2.57M 4.86M 336M 4.91M 12.95M 169M 13.17M 12.88M 563M |
| Net Debt | - | - |
Employees
-
Sector
Pharmaceuticals
Calendar
Select your edition
All financial news and data tailored to specific country editions
